The efficacy and safety of PD-1/PD-L1 inhibitors plus anti-angiogenic with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line therapy for advanced non-small cell lung cancer patients were further investigated in this study using real-world clinical data analysis. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.